Our specific objectives were to induce NAFLD in vivo and in vitro to study the underlying mechanisms whereby HX could positively affect the disease, focusing on the use of network pharmacology and experimental validation. The gene discussed is HPX; the disease is metabolic dysfunction-associated steatotic liver disease.